<?xml version='1.0' encoding='utf-8'?>
<document id="32035014"><sentence text="Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects." /><sentence text="ACT-539313 is a potent and selective orexin-1 receptor antagonist" /><sentence text=" CYP3A is the major cytochrome P450 (CYP) enzyme involved in the metabolism and clearance of ACT-539313 in man" /><sentence text=" The main objective of this study was to investigate the effect of ACT-539313 on the pharmacokinetics of orally administered midazolam"><entity charOffset="125-134" id="DDI-PubMed.32035014.s4.e0" text="midazolam" /></sentence><sentence text=" Thereby, this single-center, open-label, fixed-sequence study investigated the CYP3A interaction potential of ACT-539313 following single- (on day 2) and repeated-dose (on day 11) twice-daily administration of 200 mg ACT-539313" /><sentence text=" Exposure to midazolam was higher during concomitant administration of single as well as after repeated doses of ACT-539313 over 10 days compared to midazolam alone (day 1)"><entity charOffset="13-22" id="DDI-PubMed.32035014.s6.e0" text="midazolam" /></sentence><sentence text=" In the presence of ACT-539313, the geometric mean ratio of the maximum plasma concentration and the area under the plasma concentration-time curve from time 0 to 24 hours increased by 1"><entity charOffset="20-30" id="DDI-PubMed.32035014.s7.e0" text="ACT-539313" /></sentence><sentence text="18- and 1" /><sentence text="79-fold on day 2, and by 2" /><sentence text="13- and 4" /><sentence text="54-fold on day 11, respectively" /><sentence text=" A similar outcome was also shown in the additionally evaluated urinary 6β-hydroxycortisol/cortisol ratio (6β-CR), as the geometric mean ratio of the 6β-CR showed a decrease to 0"><entity charOffset="72-90" id="DDI-PubMed.32035014.s12.e0" text="6β-hydroxycortisol" /><entity charOffset="91-99" id="DDI-PubMed.32035014.s12.e1" text="cortisol" /><pair ddi="false" e1="DDI-PubMed.32035014.s12.e0" e2="DDI-PubMed.32035014.s12.e0" /><pair ddi="false" e1="DDI-PubMed.32035014.s12.e0" e2="DDI-PubMed.32035014.s12.e1" /></sentence><sentence text="78 on day 2 and to 0" /><sentence text="61 on day 11" /><sentence text=" The most commonly reported adverse events (AEs) included somnolence and headache" /><sentence text=" All AEs were transient and of mild intensity" /><sentence text=" No treatment-related effects on vital signs, clinical laboratory, and electrocardiogram were observed" /><sentence text=" In summary, the observed corresponding decrease of both the validated, exogenous (midazolam/1-hydroxymidazolam ratio) and a frequently used endogenous (6β-CR) marker of CYP3A activity is indicative of CYP3A inhibition occurring after ACT-539313 treatment"><entity charOffset="83-92" id="DDI-PubMed.32035014.s18.e0" text="midazolam" /><entity charOffset="93-111" id="DDI-PubMed.32035014.s18.e1" text="1-hydroxymidazolam" /><pair ddi="false" e1="DDI-PubMed.32035014.s18.e0" e2="DDI-PubMed.32035014.s18.e0" /><pair ddi="false" e1="DDI-PubMed.32035014.s18.e0" e2="DDI-PubMed.32035014.s18.e1" /></sentence><sentence text="" /></document>